Unprecedented results against a stubbornly hard-to-treat cancer are boosting optimism that other challenging tumors will be ...

An experimental drug that could be a breakthrough in the treatment of one of the deadliest known cancers is driving demand at clinics while awaiting full government approval. Daraxonrasib, a drug that ...

An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.

Get unlimited access to ad-free articles and exclusive content. An AI model developed at the Mayo Clinic in Rochester, Minnesota, detected abnormalities on patients’ CT scans up to three years before ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.” Daraxonrasib, an ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. All your photos are now in play. Updated on Apr. 20 with additional analysis on Google’s new ...

When former Nebraska Sen. Ben Sasse was diagnosed with Stage 4 pancreatic cancer in December, he was given three to four months to live. Now a drug by Revolution Medicines is giving him precious more ...

An experimental treatment has doubled one-year survival rates for pancreatic cancer, one of the deadliest types of cancer, a new study reports. The drug, called elraglusib, targets the protective web ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...